Remdesivir News and Research

RSS

Melatonin as a safe and potentially life-saving treatment for COVID-19

A new study discusses the possible role of melatonin, an antioxidant and anti-inflammatory agent, in treating COVID-19.

24 Feb 2022

Foundational characterization of a new bat-borne ebolavirus and its potential as a human pathogen

Researchers sought to evaluate the zoonotic potential of BOMV to assess the level of risk to public health.

24 Feb 2022

Response of peripheral immune cells to ex vivo SARS-CoV-2 exposure compared to SARS-CoV

Researchers characterized the responses of the PBMCs at the individual cell and cell type levels against SARS-CoV-2 and SARS-CoV ex vivo.

18 Feb 2022

Ensitrelvir, a novel SARS-CoV-2 antiviral

S-217622 reduces the viral load and help alleviate the severity of SARS-CoV-2 in infected hamsters.

17 Feb 2022

The in vitro selection of a remdesivir-resistant SARS-CoV-2 mutation

Researchers select and study an RDV-resistant virus by serial passaging of wild type SARS-CoV-2 in the presence of increasing concentrations of RDV.

15 Feb 2022

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

A new study published demonstrated the in vitro potencies of RDV and GS-441524 through PRA, and nucleoprotein ELISA against SARS-CoV-2 and other VOC/VOIs isolates with specific substitutions in Nsp12.

15 Feb 2022

Researchers identify a powerful combination of antivirals to treat COVID-19

Researchers at the University of Maryland School of Medicine and University of Pennsylvania Perelman School of Medicine have identified a powerful combination of antivirals to treat COVID-19.

14 Feb 2022

Nitazoxanide shows promise for COVID-19 treatment in animal model

In a recent study posted to the bioRxiv* pre-print server, researchers demonstrated that Nitazoxanide (NTZ), an oral drug, broadly inhibits replication of several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) in preclinical models of infection.

13 Feb 2022

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

A survey demonstrated that patients with systemic autoimmune rheumatic diseases commonly experience augmented disease severity and disrupted treatment regimens of disease-modifying antirheumatic drugs after acute COVID-19 course.

11 Feb 2022

Properties and pharmacokinetics an oral drug candidate for COVID-19 treatment

Researchers studied the preclinical PK) and in vitro ADME properties of GS-441524, a potential oral drug for COVID-19 treatment.

10 Feb 2022

Wearable devices can help monitor wellness during recovery from COVID-19

Researchers compare the resting heart changes in individuals with COVID-19 with individuals diagnosed with seasonal influenza.

9 Feb 2022

Researchers identify a potent new combination of antiviral drugs to combat SARS-CoV-2

The recent success of Paxlovid has encouraged researchers to develop new anti-covid drugs. With this in mind, scientists from the University of Pennsylvania have been investigating a new synergistic treatment. Their research is released early as an unedited version of the manuscript to be published in the journal Nature.

9 Feb 2022

Super-resolution imaging of the human coronavirus genome during infection

Using high-throughput confocal super-resolution microscopy, scientists visualize the genomic material of the human coronavirus HCoV-229E.

9 Feb 2022

How SARS-CoV-2 infection progresses throughout the respiratory system

Researchers discuss the progression of SARS-CoV-2 infection throughout the respiratory epithelium.

9 Feb 2022

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

A new article reviewed the innate immune detection and signaling pathways that the host uses against SARS-CoV-2.

7 Feb 2022

UK's most vulnerable will soon be able to access second ground-breaking antiviral

Thousands of the country's most vulnerable will be able to access the UK's second ground-breaking antiviral - Pfizer's PF-07321332+ritonavir (Paxlovid) - from Thursday 10 February, the government has announced today.

28 Jan 2022

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

Researcher discusses several promising therapeutic candidates that have been proposed for the treatment of patients infected with the Omicron variant.

28 Jan 2022

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

This scanning electron microscope image shows SARS-CoV-2 (round gold particles) emerging from the surface of a cell cultured in the lab. SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19.NIAID

28 Jan 2022

Hospitalized COVID-19 patients may derive modest benefit from convalescent plasma, study shows

Transfusions of blood plasma donated by people who have recovered from COVID-19 may help patients hospitalized with the virus, a new international study shows.

25 Jan 2022

Study explains why Omicron infections are less likely to cause severe disease

A new study by researchers from the University of Kent and the Goethe University Frankfurt shows that the SARS-CoV-2 Omicron variant is less effective than Delta at blocking a cellular defense mechanism against viruses, the so-called “interferon response”.

24 Jan 2022

Remdesivir News and Research

Melatonin as a safe and potentially life-saving treatment for COVID-19

Foundational characterization of a new bat-borne ebolavirus and its potential as a human pathogen

Response of peripheral immune cells to ex vivo SARS-CoV-2 exposure compared to SARS-CoV

Ensitrelvir, a novel SARS-CoV-2 antiviral

The in vitro selection of a remdesivir-resistant SARS-CoV-2 mutation

Antiviral activity assessment of remdesivir against 10 current and former SARS-CoV-2 variant clinical isolates

Researchers identify a powerful combination of antivirals to treat COVID-19

Nitazoxanide shows promise for COVID-19 treatment in animal model

The impact of COVID-19 on people with systemic autoimmune rheumatic diseases

Properties and pharmacokinetics an oral drug candidate for COVID-19 treatment

Wearable devices can help monitor wellness during recovery from COVID-19

Researchers identify a potent new combination of antiviral drugs to combat SARS-CoV-2

Super-resolution imaging of the human coronavirus genome during infection

How SARS-CoV-2 infection progresses throughout the respiratory system

Innate immune processes involved in SARS-CoV-2 recognition and resultant inflammation

UK's most vulnerable will soon be able to access second ground-breaking antiviral

Potential therapy candidates for patients infected with the SARS-CoV-2 Omicron variant

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

Hospitalized COVID-19 patients may derive modest benefit from convalescent plasma, study shows

Study explains why Omicron infections are less likely to cause severe disease

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News